Soleo Health Among First to Offer HEMA Biologics’™ SEVENFACT®, a Newly Released Treatment for Bleeding Disorders
Summary
FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, announced today it is now offering SEVENFACT, a newly released drug by HEMA BiologicsTM for the treatment and control of bleeding disorders in adolescent and adult patients with Hemophilia A or B with inhibitors. SEVENFACT is designed to bypass the presence of an inhibitor that some patients produce against the clotting factor concentrates they have used as a treatment, thereby helping to treat their bleeding disorders. “Soleo Health is on the cutting edge in terms of forging manufacturer relationships and bringing the latest in clinical advancements to our patients and prescribing physicians. As inhibitor patients continue to suffer the consequences of bleeding, bypassing agents will remain an essential part of disease management,” explains Dr. Allan Alexander, vice president of medical affairs at HEMA Biologics. Soleo Health operates 20 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by The Joint Commission.